Research at Riboxx

The fields of research at Riboxx encompass molecular biology, cell biology, biochemistry, and structural biology. Our initial scientific work in the field of immunotherapy of cancer dealt with tumor-specific antigens such as survivin. Moreover, the scientists working at Riboxx have a deep and solid expertise in virology, particularly molecular and structural virology. Further fields of interests are RNA in a broad sense, in particular as to its engineering and synthesis using enzymatic approaches.

Riboxx has acquired grants from the German Ministry of Research and Education (BMBF), and is partner in two FP7-founded projects (SILVER and EUVIRNA).

 Intellectual property

The IP portfolio of Riboxx relates to various technologies encompassing the fields of LIFE SCIENCE and PHARMACEUTICALS. The IP portfolio of Riboxx relates mainly to three fields of inventions:

• RNA/siRNA/miRNA engineering, synthesis and analytics
• Biocatalysis of chemically modified RNA
• RNA molecular detection  

The IP portfolio of Riboxx includes 12 international patent families as well as many brands among them Riboxx®, RNA interference in a box®, IBONI®, IVORI®, TENPORA®, ENOVA®, CONTRAmir®, pre-CONmir®, CONmir®, and RIBOXXIM®.